FDA advisory committee (AdCom)

An FDA advisory committee (AdCom) is a panel of independent experts, such as physicians, statisticians and patient and consumer representatives, that the FDA convenes to review a product application in a public meeting and give non-binding advice. Panels are organized by therapeutic area; the Oncologic Drugs Advisory Committee (ODAC) is one of the best known.

How it works

The FDA decides when to call a meeting, often for first-in-class drugs, close calls on efficacy or safety, or products raising broad public health questions. Meetings are announced in the Federal Register. Shortly before the meeting, typically two business days, the FDA posts briefing documents from both its reviewers and the sponsor. At the meeting the sponsor presents, FDA reviewers present, the public comments, and the panel discusses and votes on questions posed by the FDA, such as whether the data show a favorable benefit-risk profile.

The vote is advisory. The FDA usually acts in line with its panels but not always. A well-known exception: an FDA panel voted overwhelmingly against Biogen's Alzheimer's drug aducanumab in November 2020, and the agency granted it accelerated approval in June 2021.

Why it matters for traders

AdComs create two catalysts ahead of the PDUFA date:

• Briefing documents. The FDA reviewers' tone is scrutinized line by line, and stocks often move sharply on release day.
• The vote. Usually announced live, with trading often halted during the meeting. A negative vote raises the odds of a complete response letter.

The specific question wording and the margin of the vote both matter.

Example

Northwind Therapeutics (NWTX) faces an AdCom three months before its PDUFA date. Briefing documents flag a safety imbalance, and shares fall 20%. At the meeting, the panel votes 9 to 4 that benefits outweigh risks, and NWTX recovers most of the drop when trading resumes.

FAQ

Does the FDA have to follow an advisory committee vote?

No. The vote is non-binding, though the FDA follows its panels in most cases.

Does every drug get an advisory committee?

No. Most approvals happen without one; the FDA convenes panels selectively.